166 related articles for article (PubMed ID: 8315436)
1. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment.
Weijl NI; Van der Harst D; Brand A; Kooy Y; Van Luxemburg S; Schroder J; Lentjes E; Van Rood JJ; Cleton FJ; Osanto S
J Clin Oncol; 1993 Jul; 11(7):1376-83. PubMed ID: 8315436
[TBL] [Abstract][Full Text] [Related]
2. Thyroid functions in patients treated with interleukin-2 and lymphokine-activated killer cells.
Kung AW; Lai CL; Wong KL; Tam CF
Q J Med; 1992 Jan; 82(297):33-42. PubMed ID: 1332102
[TBL] [Abstract][Full Text] [Related]
3. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma.
Scalzo S; Gengaro A; Boccoli G; Masciulli R; Giannella G; Salvo G; Marolla P; Carlini P; Massimini G; Holdener EE
Eur J Cancer; 1990; 26(11-12):1152-6. PubMed ID: 2149997
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
5. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
[TBL] [Abstract][Full Text] [Related]
7. Lithium, thyroid function and antithyroid antibodies.
Leroy MC; Villeneuve A; Lajeunesse C
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(4):483-90. PubMed ID: 3406426
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
Thompson JA; Bianco JA; Benyunes MC; Neubauer MA; Slattery JT; Fefer A
Cancer Res; 1994 Jul; 54(13):3436-41. PubMed ID: 8012963
[TBL] [Abstract][Full Text] [Related]
10. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer.
Franzke A; Peest D; Probst-Kepper M; Buer J; Kirchner GI; Brabant G; Kirchner H; Ganser A; Atzpodien J
J Clin Oncol; 1999 Feb; 17(2):529-33. PubMed ID: 10080596
[TBL] [Abstract][Full Text] [Related]
11. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
13. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Pani F; Atzori F; Baghino G; Boi F; Tanca L; Ionta MT; Mariotti S
Thyroid; 2015 Nov; 25(11):1255-61. PubMed ID: 26414109
[TBL] [Abstract][Full Text] [Related]
14. Amiodarone-induced thyroid dysfunction: diagnostic role of free serum thyroid hormone levels and pathogenetic significance of antithyroid antibodies.
Foresti V; Carini L; Lovagnini-Scher CA; Parisio E; Scolari N
Int J Clin Pharmacol Res; 1986; 6(3):241-7. PubMed ID: 3744627
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of autoimmune hypothyroidism induced by lymphokine-activated killer (LAK) cell therapy: in vitro inhibition of human thyroid function by interleukin-2 in the presence of autologous intrathyroidal lymphocytes.
Sato K; Yamazaki K; Shizume K; Yamakawa Y; Satoh T; Demura H; Kanaji Y; Obara T; Fujimoto Y; Aiba M
Thyroid; 1993; 3(3):179-88. PubMed ID: 8257856
[TBL] [Abstract][Full Text] [Related]
16. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.
Atkins MB; Mier JW; Parkinson DR; Gould JA; Berkman EM; Kaplan MM
N Engl J Med; 1988 Jun; 318(24):1557-63. PubMed ID: 3259674
[TBL] [Abstract][Full Text] [Related]
17. Thyroid disease and high concentration of serum thyrotrophin in a population sample of women. A 4-year follow-up.
Nyström E; Bengtsson C; Lindquist O; Noppa H; Lindstedt G; Lundberg PA
Acta Med Scand; 1981; 210(1-2):39-46. PubMed ID: 7293826
[TBL] [Abstract][Full Text] [Related]
18. Characterization of thyroid-stimulating blocking antibodies that appeared during transient hypothyroidism after radioactive iodine therapy.
Kung AW; Lau KS; Kohn LD
Thyroid; 2000 Oct; 10(10):909-17. PubMed ID: 11081257
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin levels are similar in goitrous euthyroid patients with or without thyroid antibodies, as well as in hypothyroid patients.
Pantazi H; Papapetrou PD
Eur J Endocrinol; 1998 May; 138(5):530-5. PubMed ID: 9625364
[TBL] [Abstract][Full Text] [Related]
20. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
Jacobs EL; Clare-Salzler MJ; Chopra IJ; Figlin RA
J Immunother (1991); 1991 Dec; 10(6):448-55. PubMed ID: 1768679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
